stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Book value per share
AstraZeneca PLC's book value per share at the end of fiscal 2025 was 31.4×, up 19.2% from 26.4× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 33.4×. Over the past ten years it has ranged from 11.1× (fiscal 2018) to 31.4× (fiscal 2025) — the current reading is the highest in ten years. AstraZeneca PLC ranks 5th of 21 Drug Manufacturers General companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 31.4× | 19.20% |
| FY2024 | 26.4× | 4.29% |
| FY2023 | 25.3× | 5.62% |
| FY2022 | 23.9× | (13.59%) |
| FY2021 | 27.7× | 132.45% |
| FY2020 | 11.9× | 6.24% |
| FY2019 | 11.2× | 1.21% |
| FY2018 | 11.1× | (15.68%) |
| FY2017 | 13.1× | (0.24%) |
| FY2016 | 13.2× | (10.01%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 33.4× | 2.87% |
| Jun 2026 | 32.5× | 6.16% |
| Mar 2026 | 30.6× | (2.74%) |
| Dec 2025 | 31.5× | 6.11% |
| 43 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| AZN AstraZeneca PLC | 33.4× |
| AMGN Amgen Inc. compare | 26.5× |
| NVS Novartis AG compare | 19.8× |
| MRK Merck & Co., Inc. compare | 17.0× |
| PFE Pfizer Inc. compare | 15.7× |
| BMY Bristol Myers Squibb Company compare | 11.5× |
| GILD Gilead Sciences, Inc. compare | 10.4× |
| NVO Novo Nordisk A/S compare | 7.8× |
| ABBV AbbVie Inc. compare | −2.6× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement